A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy

Sang Hoon Park, Yoon Tae Jeen, Hwang Rae Chun, Dong Il Kim, Chang Won Baeck, Yong Sik Kim, Hoon-Jai Chun, Hong Sik Lee, Soon-Ho Um, Jai Hyun Choi, Chang Duck Kim, Ho Sang Ryu, Jin Hai Hyun

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.

Original languageEnglish
Pages (from-to)297-301
Number of pages5
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume46
Issue number4
Publication statusPublished - 2005 Jan 1

Fingerprint

Crohn Disease
Fistula
Young Adult
Therapeutics
Inflammatory Bowel Diseases
Intravenous Infusions
Pharmaceutical Preparations
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Cytokines
Pediatric Crohn's disease
Infliximab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy. / Park, Sang Hoon; Jeen, Yoon Tae; Chun, Hwang Rae; Kim, Dong Il; Baeck, Chang Won; Kim, Yong Sik; Chun, Hoon-Jai; Lee, Hong Sik; Um, Soon-Ho; Choi, Jai Hyun; Kim, Chang Duck; Ryu, Ho Sang; Hyun, Jin Hai.

In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 46, No. 4, 01.01.2005, p. 297-301.

Research output: Contribution to journalArticle

Park, Sang Hoon ; Jeen, Yoon Tae ; Chun, Hwang Rae ; Kim, Dong Il ; Baeck, Chang Won ; Kim, Yong Sik ; Chun, Hoon-Jai ; Lee, Hong Sik ; Um, Soon-Ho ; Choi, Jai Hyun ; Kim, Chang Duck ; Ryu, Ho Sang ; Hyun, Jin Hai. / A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy. In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi. 2005 ; Vol. 46, No. 4. pp. 297-301.
@article{74826499e7e9416ba670ee6e22a4cd06,
title = "A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy",
abstract = "Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.",
author = "Park, {Sang Hoon} and Jeen, {Yoon Tae} and Chun, {Hwang Rae} and Kim, {Dong Il} and Baeck, {Chang Won} and Kim, {Yong Sik} and Hoon-Jai Chun and Lee, {Hong Sik} and Soon-Ho Um and Choi, {Jai Hyun} and Kim, {Chang Duck} and Ryu, {Ho Sang} and Hyun, {Jin Hai}",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "46",
pages = "297--301",
journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",
issn = "1598-9992",
publisher = "Korean Society of Gastroenterology",
number = "4",

}

TY - JOUR

T1 - A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy

AU - Park, Sang Hoon

AU - Jeen, Yoon Tae

AU - Chun, Hwang Rae

AU - Kim, Dong Il

AU - Baeck, Chang Won

AU - Kim, Yong Sik

AU - Chun, Hoon-Jai

AU - Lee, Hong Sik

AU - Um, Soon-Ho

AU - Choi, Jai Hyun

AU - Kim, Chang Duck

AU - Ryu, Ho Sang

AU - Hyun, Jin Hai

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.

AB - Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.

UR - http://www.scopus.com/inward/record.url?scp=33644921817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644921817&partnerID=8YFLogxK

M3 - Article

C2 - 16247274

AN - SCOPUS:33644921817

VL - 46

SP - 297

EP - 301

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

SN - 1598-9992

IS - 4

ER -